Sunday, May 19, 2013 Last update: Yesterday, 8:04 PM
Company Tech News as it Breaks
Janssen Therapeutics
News articles for Janssen Therapeutics:
Wednesday, April 24, 2013
- Janssen Therapeutics LINCC(TM) Program Continues its Commitment to Underserved Populations with Charitable Contributions to 16 HIV/AIDS Organizations Across the U.S.TITUSVILLE, N.J., April 24, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care (LINCC(TM)) Initiative. The LINCC(TM) Initiative is part of the Janssen Therapeutics commitment to improving access to care in ... read more
Monday, December 31, 2012
- FDA Grants Accelerated Approval for SIRTURO(TM) (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant TuberculosisTITUSVILLE, N.J., Dec. 31, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to SIRTURO(TM) (bedaquiline) Tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval ... read more
Monday, December 10, 2012
- FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult PatientsTITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the ... read more